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Systemic lupus erythematosus (SLE) is a
chronic, systemic autoimmune disorder char-
acterized by exacerbations and remissions of
varying intensity and duration. Its clinical
manifestations are almost invariably accompa-
nied by the presence of autoantibodies
directed at a wide array of self-components,
including cell-surface structures (surface pro-
teins and phospholipids on lymphocytes) and
intracellular molecules (DNA, histones, and
RNA) (von Muhlen and Tan 1995). Among
its many manifestations, the presence of renal
disease in the form of glomerulonephritis is
used as a major predictor of morbidity and
mortality (Ansell et al. 1996).
Current evidence suggests that a combina-
tion of factors plays a role in the development
of autoimmunity in SLE, including genetic,
environmental, hormonal, and viral inﬂuences
(D’Cruz 2000; Roubinian et al. 1978).
Although SLE can be seen in either sex at any
age, females are at a much greater risk than are
males, with the highest incidence occurring in
women in their childbearing years (Lahita
1996). Although the precise factors responsi-
ble for the increased incidence of disease in
women remain to be clariﬁed, several lines of
evidence suggest that sex hormones may be a
predisposing factor (Cutolo et al. 1995; Rood
et al. 1998; Sanchez-Guerrero et al. 1997).
An influence of estrogen status on the
development of SLE is clearly demonstrated
in murine SLE models, such as the (NZB ×
NZW)F1 mouse. Although most (NZB ×
NZW)F1 mice develop SLE spontaneously
and experience premature mortality, females
develop more severe disease and succumb at
an earlier age than do males (Roubinian et al.
1978). Androgen treatment of females
decreases autoantibody levels, diminishes renal
disease, and improves survival (Roubinian et al.
1979). In males, castration or administration of
estrogen accelerates development of SLE.
Several environmental contaminants have
been found to produce estrogen-like effects,
including some of the organochlorine pesti-
cides (OCPs) (e.g., Andersen et al. 2002;
Soto et al. 1994). Given the influence of
estrogen on SLE in experimental models, we
hypothesized that OCPs with estrogenic
effects would similarly accelerate lupus devel-
opment. As an initial test of this hypothesis,
three different OCPs were tested for effects
on the time course of development of lupus
in female (NZB × NZW)F1 mice, o,p´-
dichlorodiphenyltrichloroethane (o,p´-DDT),
methoxychlor, and chlordecone. Each of
these pesticides had been shown previously to
possess estrogenic activity in vivo (e.g.,
Cummings 1997; Das-Sanjoy et al. 1998;
Flaws et al. 1997; Morozova et al. 1997). Mice
were ovariectomized to reduce the potentially
confounding effects of cycling endogenous
estrogen and were treated chronically with one
of the pesticides or with 17β-estradiol as a pos-
itive control. Time to development of clinical
SLE, manifested as terminal immune complex
glomerulonephritis, was measured. In these
experiments, all of the OCPs caused accelera-
tion of time to development of SLE, with
chlordecone producing the greatest response.
More detailed, follow-up experiments were
conducted with chlordecone to examine dose–
response relationships and verify estrogenic
effects. The results of these experiments,
reported here, indicate an effect of the OCPs
to speed progression of autoimmunity in
(NZB × NZW)F1 mice.
Materials and Methods
Mice. Female (NZB × NZW)F1 mice,
6–8 weeks of age, were obtained from the
Jackson Laboratory (Bar Harbor, ME). Mice
were housed in temperature-, light-, and
humidity-controlled animal quarters under spe-
ciﬁc-pathogen-free conditions. Polycarbonate
cages with ground corncob bedding were
used, and mice had free access to food and
water for the duration of the experiment. All
procedures were approved by the institutional
animal care and use committee of the
University of Florida.
Ovariectomy. All animals were subjected
to ovariectomy or a sham-operation approxi-
mately 1 week after they were received.
Surgery was performed under anesthesia with
a mixture of ketamine (133 mg/kg) and
xylazine (13 mg/kg) administered intra-
peritoneally. All procedures were identical for
ovariectomized and sham-surgery mice,
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Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects women more fre-
quently than men. In the (NZB × NZW)F1 mouse, a murine SLE model, the presence or absence
of estrogen markedly inﬂuences the rate of progression of disease. Three organochlorine pesticides
with estrogenic effects were administered chronically to ovariectomized female (NZB × NZW)F1
mice, and we measured the time to development of renal disease, the principal clinical manifesta-
tion of lupus in this model. Treatment with chlordecone, methoxychlor, or o,p´-dichlorodiphenyl-
trichloroethane (o,p´-DDT) signiﬁcantly decreased the time to onset of renal impairment, as did
treatment with 17β-estradiol used as a positive control. In an expanded study of chlordecone, we
found a dose-related early appearance of elevated anti–double-strand DNA autoantibody titers that
corresponded with subsequent development of glomerulonephritis. Immunohistoﬂuorescence con-
ﬁrmed early deposition of immune complexes in kidneys of mice treated with chlordecone. These
observations are consistent with an effect of these organochlorine pesticides to accelerate the natural
course of SLE in the (NZB × NZW)F1 mouse. Although we originally hypothesized that the effect
on progression of autoimmunity was due to estrogenic properties of the pesticides, autoimmune
effects and estrogenicity, assessed through measurement of uterine hypertrophy, were not well cor-
related. This may indicate that uterine hypertrophy is a poor indicator of comparative estrogenic
effects of organochlorine pesticides on the immune system, or that the pesticides are inﬂuencing
autoimmunity through a mode of action unrelated to their estrogenicity. Key words: autoimmunity,
chlordecone, DDT, estrogenicity, glomerulonephritis, kepone, methoxychlor, organochlorine pesti-
cides, systemic lupus erythematosus. Environ Health Perspect 113:323–328 (2005).
doi:10.1289/ehp.7347 available via http://dx.doi.org/ [Online 2 December 2004]except that in the latter case, ovaries were
exposed but not ligated and removed.
Test materials and treatments. We pur-
chased chlordecone (described as 99.2% pure)
from Crescent Chemical (Islandia, NY).
methoxychlor (95%) from Sigma Chemical
Co. (St. Louis, MO), and o,p´-DDT (98%)
from Chem Service (Westchester, PA). We
conﬁrmed the identity of each material as sup-
plied by gas chromatography–mass spectrome-
try. Each pesticide was formulated in speciﬁed
amounts into sustained-release pellets (60-day
release) by Innovative Research of America
(Sarasota, FL). Control pellets (matrix only),
and pellets containing 17β-estradiol were also
obtained from this source. One week after
ovariectomy, mice were implanted subcuta-
neously with an OCP, 17β-estradiol, or con-
trol pellet. For implantation, mice were lightly
anesthetized with methoxyﬂurane, and the pel-
let was placed beneath the skin dorsally above
the shoulders. Implants were replaced every
60 days for the duration of the experiment.
Evaluation of renal function. Once the pel-
lets were implanted, we systematically evaluated
the course of the disease. The appearance of
renal disease was detected through monthly
measurement of urine protein and blood urea
nitrogen (BUN). Urine was collected from
spontaneous expression during manual
restraint. Proteinuria was measured by dipstick
method using Albustix (Bayer Corp., Elkhart,
IN). Blood samples were obtained from tail
nicks, and BUN was measured using Azostix
(Bayer Corp.). Body weights were also recorded
monthly. If animals showed weight loss of
≥ 10% or worsening renal function by either
BUN or proteinuria, they were reassessed every
2 weeks until termination. Mice were eutha-
nized when the BUN reached or exceeded
50 mg/dL and/or proteinuria reached or
exceeded 2,000 mg/dL. In the initial study of
three OCPs, surviving mice were euthanized
8 months after the start of treatment. In the
second study focusing on chlordecone, the
experiment was ended and surviving mice euth-
anized after 7 months of treatment.
Histology. At defined time points, mice
from each group were euthanized, and their
kidneys were preserved in 10% buffered forma-
lin. Tissue samples were processed routinely,
sectioned, mounted on glass slides, and stained
with hematoxylin and eosin or periodic acid
Schiff (PAS) for light microscopic examination.
All kidney sections were viewed and scored by a
pathologist in a blinded examination. The
glomeruli were categorized using a modified
World Health Organization classification
(Churg et al. 1995) as having no damage,
mesangiopathic damage, or proliferative dam-
age. In addition to the severity of the glomeru-
lar damage, the amount of renal damage was
quantiﬁed using the following scale: 1+, 1–9%
of glomeruli affected; 2+, 10–24% of glomeruli
affected; 3+,(25–49% of glomeruli affected;
and 4+, ≥ 50% of glomeruli affected.
Autoantibody titers. We measured auto-
antibody [IgG anti–double-strand DNA
(anti-dsDNA)] titers in serum in some treat-
ment groups using indirect ELISA (enzyme-
linked immunosorbent assay). Immulon 2
microtiter plates (Dynatech Laboratories,
Inc., Chantilly, VA) were coated overnight at
4°C with a 1:10 (vol/vol) dilution of poly-L-
lysine at 100 µL/well. Between all steps,
microplates were washed three times with
borate-buffered saline (25 mM Na2B4O7,
75 mM NaCl, 100 mM H3BO3, pH 8.4) con-
taining 0.05% Tween 20. After addition of calf
thymus DNA (50 µL/well at a concentration
of 20 µg/mL), the plate was blocked with
100 µL/well of 3% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS).
Dilutions (1:200) of serum samples were pre-
pared in PBS and incubated in the appropriate
wells at room temperature for 1 hr. The sec-
ondary antibody (goat anti-mouse IgG peroxi-
dase conjugated Fc gamma specific; Jackson
ImmunoResearch Laboratories, West Grove,
PA) was diluted to 1:5,000 (vol/vol) in PBS
and added at 50 µL/well. The developing
solution consisted of o-phenylene diamine at
0.4 mg/mL PC buffer (4.7 g/L citric acid and
13.8 g/L sodium phosphate dibasic hepta-
hydrate, pH 5.1) with 0.01% H2O2. The
substrate turnover was determined by the
difference between the OD450 (optical den-
sity) and OD620 on a Molecular Devices
(Sunnyvale, CA) microplate reader. The con-
centration of antigen-speciﬁc IgG is reported
in equivalent dilution factors (EDFs) of stan-
dardized reference NZB × NZW/F1 sera.
This is deﬁned by the formula EDF = (dilu-
tion of a standard reference sera that gives the
equivalent OD of the test serum) × 104.
Immunohistofluorescence. Immune com-
plex deposition in glomeruli was visualized by
immunohistofluorescence. Renal tissue sec-
tions 7 µm in thickness were mounted to
glass slides (Fisher Scientific, Fairlawn, NJ).
Blocking solution (1% BSA, 0.1% Tween,
and 10% rat serum in PBS) was applied for
20 min. Then slides were incubated with
100 µL goat anti-mouse IgG–fluorescein
isothiocyanate antibody (Southern Biotech,
Birmingham, AL) diluted 1:40 in PBS with
1 mg/mL BSA for 30 min in a humidified
chamber. Slides were then washed three times
in PBS and once in distilled water. One drop
of glycerin was placed on the sample, and the
slide was coverslipped and examined by ﬂuo-
rescence microscopy.
Uterine hypertrophy. We conducted a
separate, short-term experiment in which we
evaluated the estrogenicity of the chlorinated
pesticides at various doses. Ovariectomized
mice were implanted with a control pellet or a
pellet containing pesticide or 17β-estradiol as
in the chronic experiments. After a 4-week
period, the mice were euthanized, and estro-
genicity of the doses was determined by mea-
surement of wet uterine weight. Immediately
after euthanasia, the uteri were excised,
trimmed free of fat, pierced, and blotted to
remove excess fluid. The body of the uterus
was cut just above its junction with the cervix
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Figure 1. Time to development of renal disease (plotted as a survival curve) in ovariectomized (NZB ×
NZW)F1 mice implanted with pellets containing (A) methoxychlor, (B) o,p´-DDT, (C) chlordecone, or
(D)1 7 β-estradiol; ovariectomized mice implanted with control pellets and sham-operated mice are shown
for comparison (n = 10/group). The time to development of renal disease was signiﬁcantly decreased in all
OCP-treated groups compared with ovariectomized controls (p < 0.05)and at the junction of the uterine horns with
the ligating clips. The uterus was then
weighed (wet weight). To compensate for the
mass of the mouse, uterine weight was
expressed as a ratio to total body weight (i.e.,
uterine mass/body mass × 1,000).
Statistical analysis. We performed statisti-
cal analysis for survival using GraphPad Prism
3 software (GraphPad Software Inc., San
Diego, CA). Uterine wet ratios were compared
for signiﬁcance using Dunnett’s procedure of
one-way analysis of variance (ANOVA).
Proteinuria and BUN data were tested using
Dunnett’s nonparametric procedure of the
Kruskal-Wallis ANOVA on ranks. The
autoantibody levels were natural log-trans-
formed before analysis in order to normalize
their distribution and improve the accuracy of
the analysis. After transformation, statistical
signiﬁcance was determined using Dunnett’s
method of ANOVA. Survival data were dis-
played as Kaplan-Meier survival curves. We
determined differences between survival curves
using the log rank test. For the dose–response
experiment, we also performed the log rank
test for trend.
Results
We conducted an experiment in which we
assessed the effects of chronic treatment with
chlordecone, o,p´-DDT, or methoxychlor on
time to development of lupus in ovariec-
tomized (NZB × NZW)F1 mice. The objective
of this experiment was to provide an initial test
of the hypothesis that estrogenic OCPs acceler-
ate the rate of development of disease in this
lupus model. Chronic doses of these pesticides
producing estrogenic effects in mice were not
clearly established in the literature and were
therefore estimated based upon short-term
studies in the literature of potential estrogenic
effects in vivo. Two doses of each OCP were
tested: 1.8 and 18 mg chlordecone, 0.9 and 9
mg o,p´-DDT, and 3 and 30 mg methoxy-
chlor. As a positive control, we also tested
0.1 mg 17β-estradiol. These doses were the
amount of chemical delivered over each 60-day
interval via implanted pellets. Ovariectomized
females given pellets with matrix only served as
controls, and an additional comparison group
of untreated, ovary-intact (sham operated)
females was included in the experiment. Each
treatment group contained 10 animals. Within
a few weeks of the start of the experiment,
mice treated with the 18-mg chlordecone pel-
lets developed tremors and were removed from
the study. Overt neurotoxicity was not
observed in the other treatment groups.
The primary assessment end point for this
experiment was the development of severe
renal disease, the hallmark of lupus in this ani-
mal model. Time to development of severe
renal disease for each treatment group is shown
in the form of Kaplan-Meier survival curves in
Figure 1. Ovariectomy extended substantially
the time to development of renal disease in this
mouse strain. This is evident by comparing the
time courses in Figure 1 for the ovariectomized
controls with the sham-operated (i.e., ovary
intact) comparison group. Replacement of
estrogen with 17β-estradiol (0.1 mg/pellet) in
ovariectomized mice shortened the time to
appearance of renal disease such that it was not
signiﬁcantly different from that of sham-oper-
ated mice (Figure 1D).
Treatment of ovariectomized mice with
o,p´-DDT or methoxychlor significantly
shortened the time to development of renal
disease compared with controls (Figure 1A,B).
The survival plots for o,p´-DDT–treated and
methoxychlor-treated groups were essentially
the same as the plot for the sham-operated
comparison group, suggesting an inﬂuence on
lupus development roughly equivalent to that
of endogenous estrogen. There was no signiﬁ-
cant difference in survival curves between the
two doses tested for o,p´-DDT and methoxy-
chlor, although the higher o,p´-DDT doses
appeared to result in more rapid development
of renal disease. The time to development of
renal disease in the single chlordecone-treated
group completing the study was signiﬁcantly
shorter than both the ovariectomized controls
and the untreated, sham-surgery comparison
group (Figure 1C). The difference in survival
was particularly striking after 22 weeks of
chlordecone treatment: 100% of the ovariec-
tomized controls, 60% of the mice in the
sham-surgery group, and none of the chlorde-
cone-treated mice survived to this time point.
Additional mice were implanted with
1.8 mg chlordecone or control pellets and
euthanized after 16 weeks of treatment.
Measurement of proteinuria at this time point
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Figure 2. Representative kidney sections taken from (NZB × NZW)F1 mice after 16 weeks of treatment.
(A) Sham-operated mouse. (B) Ovariectomized mouse treated with chlordecone (1.8 mg/pellet). (C and
D) Two ovariectomized mice, each treated with a control pellet. (A) and (B) show enlarged, cellular, and
sclerotic glomeruli (arrows) with tubular atrophy and dilation (asterisks). (C) and (D) show segmental
mesangial thickening, but otherwise spared, glomeruli (arrows) with normal tubules (asterisk). Sections
were stained with PAS (magniﬁcation, 400×). indicated severe renal disease in the chlorde-
cone-treated mice but not in the ovariec-
tomized controls. Renal sections from these
mice were examined by light microscopy
(Figure 2). The observations correlated well
with proteinuria ﬁndings and were consistent
with early appearance of immune complex
glomerulonephritis in chlordecone-treated
mice. All of the chlordecone-treated mice had
developed signiﬁcant proliferative glomerulo-
nephritis with ﬁbrosis, the most severe form of
glomerulonephritis in lupus. The control mice,
in contrast, showed only mesangial involve-
ment, an early or mild form of renal disease.
One control animal had evidence of prolifera-
tive glomerulonephritis, but only approxi-
mately 10% of glomeruli were affected.
In view of the particularly strong response
to chlordecone, we conducted a follow-up
experiment in which lower doses of chlorde-
cone were tested (0.01, 0.1, 0.5, and 1.0 mg
per 60-day-release pellet). The control group
(matrix-only pellets) consisted of 20 animals;
all other groups consisted of 10 animals each.
The time course for development of severe
renal disease is shown in Figure 3. Mice treated
with the 1.0 or 0.5 mg chlordecone pellets
developed renal disease significantly earlier
than did ovariectomized controls (p < 0.05).
The rate of development of lupus also
appeared to be enhanced in mice treated with
0.01 and 0.1 mg chlordecone pellets, although
the difference did not reach statistical signiﬁ-
cance. The log rank test for trend using all
three doses was statistically significant
(p < 0.03).
During the course of the follow-up experi-
ment with chlordecone, mice were bled
periodically, and the sera were tested for anti-
dsDNA by ELISA. Elevated autoantibody
titers appeared earlier in chlordecone-treated
mice than in ovariectomized controls. The
greatest difference was seen after 20 weeks of
treatment, a time point in this experiment at
which substantial differences in overt renal
disease had not yet appeared (Figure 3). Mice
treated with 1 mg chlordecone pellets had
titers significantly higher than those of con-
trols (p < 0.01) and essentially equivalent to
those in the sham-operated comparison group
(Figure 4). Autoantibody titers in mice treated
with 0.1 mg chlordecone were also elevated
compared with controls, but the difference
was not statistically signiﬁcant.
To verify that the earlier renal failure in
chlordecone-treated mice was of autoimmune
origin, a separate small cohort of (NZB ×
NZW)F1 female mice was ovariectomized and
individual animals were implanted with a con-
trol pellet or a pellet containing chlordecone
(1 mg) or estradiol (0.05 mg). Approximately
8 weeks later, at a time when some of the mice
were beginning to show proteinuria, all mice
were euthanized. The spleens were weighed,
and the kidneys were evaluated for histo-
pathology and immunostained for IgG. By
light microscopic examination, there was a
tendency toward worsened proliferative
glomerulonephritis in the chlordecone- and
estradiol-treated groups (Figure 5A). In con-
trast, less severe mesangiopathic changes were
decreased, particularly in the estradiol-treated
groups (Figure 5B). In general, proliferative
and mesangiopathic changes were not seen on
the same specimens. Proteinuria was greater in
both the chlordecone- and estradiol-treated
groups (Figure 5C), and both differences were
statistically significant when compared to
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Figure 5. Enhanced renal disease and immune complex deposition in ovariectomized, chlordecone-treated
mice after 8 weeks of treatment with control pellets or pellets containing chlordecone (1 mg/pellet) or
17β-estradiol (0.05 mg/pellet; n = 6/group). Frequency of appearance of proliferative glomerulonephritis (GN;
A), mesangiopathic glomerulonephritis (B), and proteinuria (C), and spleen weight. The frequency of occur-
rence of proteinuria was significantly increased in both chlordecone-treated and 17β-estradiol–treated
mice; spleen weight (D) was significantly increased by 17β-estradiol. (E) Immunofluorescence staining
(magniﬁcation, 200×) for IgG was absent in control mice, but present in mice treated with either chlorde-
cone or 17β-estradiol after 8 weeks of treatment; later, when renal disease developed in controls, a similar
extent of immunoﬂuorescence staining was observed.
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Figure 3. Time to development of renal disease in
ovariectomized (NZB × NZW)F1 mice (n = 20 con-
trols; n = 10 sham operated; n = 10 for each of the
chlordecone-treated groups). The time to appear-
ance of renal disease was signiﬁcantly decreased
in mice treated with the 1-mg chlordecone pellets
(p < 0.05).
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Figure 4. Serum autoantibody titers in ovariec-
tomized (NZB × NZW)F1 mice treated 20 weeks after
treatment with chlordecone. Ovariectomized mice
implanted with control pellets and sham-operated
mice are shown for comparison. Antibody titers from
mice treated with 1 mg chlordecone pellets were
significantly higher than those of ovariectomized
controls (p < 0.01).ovariectomized controls (p < 0.05). Spleen
weight (Figure 5D) was clearly increased in
the estradiol-treated group, and this reached
statistical significance (p < 0.05). We also
observed a tendency toward increased spleen
weight in the chlordecone-treated group, but it
did not reach statistical signiﬁcance (p = 0.14).
These observations were consistent with previ-
ous experiments showing similar, early devel-
opment of severe renal disease in chlordecone-
and estradiol-treated (NZB × NZW)F1 mice
(Figure 1). Immunohistoﬂuorescence analysis
of renal sections showed enhanced deposits of
IgG in the chlordecone- and estradiol-treated
groups (Figure 5E). Little or no immuno-
staining was observed in the control group at
this time point. As indicated by previous
experiments, had the control mice been
observed for longer periods, they ultimately
would have developed proteinuria and renal
disease. For perspective on the extent of
immune complex deposition in controls at
these later time points, renal sections from
controls from previous experiments, taken at
the time of development of renal disease, were
also immunostained. As shown in Figure 5E,
the immune complex deposition when renal
disease appeared was similar in control, chlorde-
cone-treated, and estradiol-treated mice. These
observations offer additional support for
the concept that chlordecone treatment results
in earlier appearance of renal disease by accel-
erating the course of autoimmune disease in a
manner similar to estrogen.
The estrogenicity of chlordecone, methoxy-
chlor, and o,p´-DDT in doses relevant to the
autoimmunity experiments was tested using
the classical end point of uterine hypertrophy.
(NZB × NZW)F1 mice were ovariectomized
and subsequently implanted subcutaneously
with a control pellet or a pellet containing one
of the pesticides. Additional mice were treated
with a pellet containing 17β-estradiol as a pos-
itive control. Six weeks after implantation,
mice were euthanized, and the uterine wet
weight and total body weight were measured.
Chlordecone and o,p´-DDT produced uterine
hypertrophy (Figure 6), although, except for
the highest doses of o,p´-DDT and chlordecone
tested, the effects were substantially less than
those produced by estradiol (0.5 mg/pellet).
Chlordecone was tested over the broadest range
of doses. Chlordecone doses of ≥ 18 mg/pellet
were required to produce significant uterine
hypertrophy, despite observations in previous
experiments that doses as low as 1 mg/pellet
were sufﬁcient to inﬂuence the rate of develop-
ment of lupus.
Discussion
It has long been hypothesized that environ-
mental factors inﬂuence the onset and course
of autoimmune diseases. Despite this, the
number of chemicals clearly shown to influ-
ence autoimmunity is relatively small.
Although a number of potential mechanisms
can be postulated, they are thought to fall
into three general categories (Rao and
Richardson 1999). The ﬁrst category is one in
which the chemical alters self antigen such
that it appears foreign to the immune system.
This can occur when small molecules act as
haptens or if exposure can cause novel cleav-
age fragments to which the immune system
was ignorant. Heavy metals, such as mercury,
may be an example of this pathway. The sec-
ond category is one in which the chemical
prevents the central tolerance of autoreactive
T or B cells and is represented by pro-
cainamide hydroxylamine. The third category
involves alteration of gene expression.
Hormones, such as estrogens, are thought to
belong to this last category (Grimaldi et al.
2002). Because many of the OCPs have been
shown to have estrogenic effects, we decided
to test representative estrogenic OCPs in the
well-characterized (NZB × NZW)F1 model
of murine lupus.
The chronic administration of chlordecone,
methoxychlor, or o,p´-DDT via implantable
pellets significantly shortened the time to
development of lupus in ovariectomized
female (NZB × NZW)F1 mice. The most
extensive experimentation was conducted
with chlordecone and showed a dose-related,
early appearance of elevated anti-dsDNA
autoantibody titers and immune complex
deposition in the kidneys. Doses of chlorde-
cone that signiﬁcantly elevated autoantibody
titers at early time points also significantly
reduced the time to subsequent development
of renal disease, which was confirmed to be
immune complex glomerulonephritis, the
hallmark for clinical lupus in this murine
model. Collectively, these observations indi-
cate that chlordecone, and probably also
methoxychlor and o,p´-DDT, acts by acceler-
ating the natural course of development of
lupus in these animals.
For chlordecone, the lowest dose per pel-
let found to produce a signiﬁcant decrease in
time to onset of renal disease was 0.5 mg.
Over the course of the experiment, mice
weighed on average about 42 g, resulting in a
dosing rate per unit body weight of approxi-
mately 0.20 mg/kg/day. The next lower dose
of chlordecone tested, 0.1 mg per pellet (or
about 0.04 mg/kg/day), might be considered
a no observable effect level (NOEL) from this
experiment. However, there was evidence for
an effect at this level and even at the lowest
dose of chlordecone tested (0.01 mg/pellet).
It is possible that with the use of larger treat-
ment groups, effects from these lower doses
might also reach statistical significance.
Other effects of chlordecone, such as renal
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Figure 6. Uterine hypertrophy in ovariectomized (NZB × NZW)F1 mice 6 weeks after administration of pel-
lets containing (A) methoxychlor, (B) o,p´-DDT, and (C) higher and (D) lower doses of chlordecone. Results
from controls and 17β-estradiol–treated mice are reproduced in A–C to facilitate comparison with OCP-
treated mice. Compared with controls, uterine weights were signiﬁcantly increased in mice treated with
0.05 mg estradiol, 10 mg methoxychlor, 0.9 and 9.0 mg o,p´-DDT, and 36 mg chlordecone.and liver toxicity, are generally associated with
chronic chlordecone doses of 0.05 mg/kg/day
or higher in rodents [Agency for Toxic
Substances and Disease Registry (ATSDR)
1995].
For both methoxychlor and o,p´-DDT,
doses spaced about 10-fold apart produced
essentially equivalent responses. This suggests
either that the effect is not dose related or that
the response from the doses tested is near the
maximum for these pesticides. Because the
lower doses produced a significant effect, a
NOEL for acceleration of autoimmunity by
these pesticides cannot be determined from
this study. It is worthwhile noting that the
lower dose of methoxychlor tested (3 mg/pel-
let, or approximately 1.2 mg/kg/day) is 4-fold
lower than the NOEL used by the U.S.
Environmental Protection Agency (EPA) in
developing an oral reference dose for methoxy-
chlor (U.S. EPA 2004). This suggests that an
effect on autoimmunity might be a sensitive
toxic end point (an effect that occurs at doses
lower than other adverse effects) for methoxy-
chlor, and therefore of particular interest for
risk assessment. o,p´-DDT decreased the time
to development of lupus at a dosing rate of
0.9 mg/pellet (or ~ 0.35 mg/kg/day). This is
similar to the lowest observable effect level for
p,p´-DDT (0.25 mg/kg/day) identiﬁed by the
EPA based on liver changes in rats (U.S. EPA
2004), suggesting that autoimmune effects
may be a sensitive end point for this OCP
as well.
Changes in the time course for develop-
ment of lupus produced by the OCPs in
ovariectomized mice were comparable to that
produced by 17β-estradiol, used in the study
as a positive control for estrogenic effects. By
and large, treatment of ovariectomized mice
with the OCPs resulted in a rate of progres-
sion of disease that resembled its natural
course in mice with intact estrogen, repre-
sented by the sham-surgery comparison
group. These observations are consistent with
an estrogenic mode of action for chlorde-
cone, methoxychlor, and o,p´-DDT effects
on autoimmunity. However, estrogenicity, as
measured by uterine hypertrophy in the
(NZB × NZW)F1 mice, correlated poorly
with effectiveness in accelerating autoimmu-
nity. Chlordecone had a greater effect on
autoimmunity than either methoxychlor or
o,p´-DDT but produced the same or less uter-
ine hypertrophy at relevant doses. At lower
doses where chlordecone was still effective
in significantly decreasing the time to onset
of renal disease, no signiﬁcant effect on uter-
ine weight was observed. The poor correla-
tion might be due simply to differences in
responsiveness to estrogenic effects by the
uterus compared with the immune system.
Unfortunately, there is little information in
the literature that offers insight regarding this
possibility.
Alternatively, the OCPs may influence
autoimmunity through a mode of action unre-
lated to their estrogenicity. The potential
importance of alternative actions is amply
demonstrated by the recent study of Sawai
et al. (2003), who fed female (NZB ×
NZW)F1 mice a diet containing bisphenol A.
Bisphenol A is produced in the manufacture
of plastics and has been shown to produce
estrogen-like effects both in vitro and in vivo.
In contrast to expectations based on estro-
genicity, bisphenol A treatment significantly
delayed the appearance of renal disease relative
to controls. The authors attributed the delay
by bisphenol A to an observed decrease in
interferon-γ production, an effect opposite of
that known to be produced by estrogen.
In the experiments reported here we used
a lupus model with a high genetic predisposi-
tion for disease. With this model, it was possi-
ble to demonstrate an effect of selected OCPs
to modify the rate of progression of disease
but not to test whether they are capable of
influencing the incidence of disease. It
remains to be determined whether these or
other OCPs can initiate, on a susceptible
genetic background, a break in tolerance—in
other words, whether they can cause SLE in a
susceptible individual that might not other-
wise develop it. Answering this question will
require testing OCPs in mouse strains with
differing genetic background with respect to
SLE susceptibility genes. Several such strains
are available (e.g., Wakeland et al. 2001), and
their use will be important in better character-
izing the autoimmune hazard associated with
OCP exposure.
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CORRECTION
Values for body weight and dosing rate for
chlordecone and the dosing rates for
methoxychlor and o,p´-DDT were incorrect
in the “Discussion” of the original manu-
script published online. They have been
corrected here.